Generic Name
Deutetrabenazine
Brand Name
Austedo
Class
Central Monoamine-Depleting Agents
Proposed Mechanism(s) of Action
Oral vesicular monoamine transporter-2 (VMAT-2) inhibitor; decreased uptake of monoamines (dopamine, norepinephrine, serotonin, histamine) into synaptic vesicles and reversible depletion of monoamine stores from nerve terminals.
Indication
Treatment of chorea associated with Huntington’s disease.
Treatment of Tardive Dyskinesia.
Off Label Use
No common off label use
Side Effects
Serious
Akathisia, agitation, restlessness, parkinsonism, and increased risk of depression and suicidal ideation in patients with Huntington disease, may prolong Q-T interval.
Common
Somnolence, fatigue, depression, dry mouth, urinary tract infection, insomnia, anxiety, bruising, constipation, dizziness, imbalance, contusion.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References and Readings
Free Drug Online and PDA Software. www.epocrates.com.
Free Drug Online and PDA Software. www.medscape.com.
Schmidt, C. (2017). First deuterated drug approved. Nature Biotechnology, 35(6), 493.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG, part of Springer Nature
About this entry
Cite this entry
Gonzalez, E.A. (2018). Deutetrabenazine. In: Kreutzer, J.S., DeLuca, J., Caplan, B. (eds) Encyclopedia of Clinical Neuropsychology. Springer, Cham. https://doi.org/10.1007/978-3-319-57111-9_9260
Download citation
DOI: https://doi.org/10.1007/978-3-319-57111-9_9260
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-57110-2
Online ISBN: 978-3-319-57111-9
eBook Packages: Behavioral Science and PsychologyReference Module Humanities and Social SciencesReference Module Business, Economics and Social Sciences